Background: Endotracheal intubation induces clinically adverse cardiovascular changes. Various pharmacological strategies for controlling these responses have been suggested with opioids being widely administered. In this study, the optimal effect-site concentration (Ce) of remifentanil for minimizing hemodynamic responses to fiberoptic nasotracheal intubation was evaluated. Methods: Thirty patients, aged 18-63 years, scheduled for elective surgery were included. Anesthesia was induced with a propofol and remifentanil infusion via target-controlled infusion (TCI). Remifentanil infusion was initiated at 3.0 ng/mL, and the response of each patient determined the Ce of remifentanil for the next patient by the Dixon up-and-down method at an interval of 0.5 ng/mL. Rocuronium was administered after propofol and remifentanil reached their preset Ce; 90 seconds later fiberoptic nasotracheal intubation was initiated. Non-invasive blood pressure and heart rate (HR) were measured at pre-induction, the time Ce was reached, immediately before and after intubation, and at 1 and 3 minutes after intubation. The up-and-down criteria comprised a 20% change in mean blood pressure and HR between just prior to intubation and 1 minute after intubation. Results: The median effective effect-site concentration (EC50) of remifentanil was 3.11 ± 0.38 ng/mL by the Dixon's up-and-down method. From the probit analysis, the EC50 of remifentanil was 3.43 ng/mL (95% confidence interval, 2.90-4.06 ng/mL). In PAVA, the EC50 and EC95 of remifentanil were 3.57 ng/mL (95% CI, 2.95-3.89) and 4.35 ng/mL (95% CI,. No remifentanil-related complications were observed. Conclusions: The EC50 of remifentanil for minimizing the cardiovascular changes and side effects associated with fiberoptic nasotracheal intubation was 3.11-3.43 ng/mL during propofol TCI anesthesia with a Ce of 4 ug/mL.
INTRODUCTION
Nasotracheal intubation is often necessary in patients undergoing oral and maxillofacial surgery [1] . The incidence of difficult airway intubation in these patients is 15.4%-16.9% due to temporomandibular joint diseases, facial abnormalities, and fractures [2, 3] . Fiberoptic bronchoscope is considered the best choice for the management of difficult airways [4] and the most reliable tool for nasotracheal intubation [5] .
Nasotracheal intubation, however, may cause hemodynamic changes. It may stimulate the sympathetic nerve system and cause a greater hypertensive response than orotracheal intubation [6] . The resultant increase in blood pressure and heart rate (HR) increases the risk of myocardial ischemia, left ventricular failure, arrhythmia, and cerebral hemorrhage [7] . The administration of local anesthetics, beta blockers, alpha-2 agonists, and opioids to prevent these problems during endotracheal intubation has been previously reported [8] [9] [10] [11] [12] [13] [14] [15] .
Remifentanil is one such opioid that may effectively ameliorate cardiovascular responses to short-term detrimental stimulations such as nasotracheal intubation [16] .
It has a rapid onset and an ultrashort duration of action; it is more stable and has a shorter context-sensitive half-time than other opioids [17] .
Previous studies have reported the use, but not the appropriate concentration of remifentanil for preventing cardiovascular changes secondary to nasotracheal intubation using a fiberscope. Therefore, the aim of this study was to evaluate the median effective effect-site concentration (EC 50 ) of remifentanil for minimizing hemodynamic responses to fiberoptic nasotracheal intubation.
METHODS
Consecutive patients scheduled for brief oral and maxillofacial surgery at Pusan National University Dental Hospital were eligible for enrollment in this study (Table   1) All patients received anesthesia with a combination of propofol and remifentanil, concomitantly with running fluid. The dose of propofol was an effect-site TCI of 4 μg/mL. Since the EC 50 of remifentanil needed to prevent cardiovascular changes after nasotracheal intubation in the presence of propofol was unknown, the sample size was calculated using the up-and-down experimental design described by Dixon [18, 19] .
After the Ce of propofol and remifentanil was reached, each patient received rocuronium 0.8 mg/kg intravenously, followed by nasotracheal intubation 90 seconds later. We initiated remifentanil infusions at 3 ng/mL; each Data are presented as frequency or mean ± standard deviation. Table 1 . Patient characteristics Fig. 1 . Up-and-down sequence. A successful response was defined as the increase of heart rate (HR) and mean blood pressure (MBP) 1 minute after nasotracheal intubation with a fiberscope that did not exceed 20% of the value just before intubation. If HR or MBP exceeded 20% of the pre-intubation value, it was defined as a failed response. A change between consecutive successful and failed responses is a "crossover" with a midpoint concentration between the successful and failed concentrations (arrows). Seven crossovers were averaged to determine the median effective effect-site concentration of remifentanil. 
RESULTS
Thirty patients were enrolled in the study initially. Three patients were excluded: one due to insufficient anesthesia, one due to a significant reduction in MBP, and one due to misuse of remifentanil concentration. Therefore, in total, 27 patients were included in the study (Table 1) .
In all patients, fiberoptic nasotracheal intubation was performed successfully, with no complications. Doseresponse data obtained by Dixon's up-and-down method are shown in Fig. 1 . The EC 50 of remifentanil required to minimize cardiovascular changes secondary to fiberoptic nasotracheal intubation, calculated from seven crossover values, was 3.11 ± 0.38 ng/mL.
In the probit analysis, the EC 50 and EC 95 of remifentanil was 3.43 ng/mL (95% CI, 2.90-4.06 ng/mL) and 4.52 ng/mL (95% CI, 3.96-9.03 ng/mL), respectively (Fig. 2) .
In PAVA, the EC 50 and EC 95 of remifentanil were 3.57 ng/mL (95% CI, 2.95-3.89) and 4.35 ng/mL (95% CI,
3.93-4.45).
Mean HR and MBP values decreased after infusion of propofol and remifentanil. These reductions were statistically significant, but were not clinically meaningful (Fig. 3) . 
DISCUSSION
Nasotracheal and endotracheal intubation activates the sympathoadrenal system, increasing catecholamine release and causing elevations in blood pressure, HR, and the incidence of arrhythmia [21] [22] [23] [24] [25] [26] . Severe sequelae such as myocardial ischemia may occur in patients with hypertension and ischemic heart disease risk factors [27] .
Furthermore, a nasotracheal tube is passed through the nose and nasopharynx, stimulating areas unaffected by orotracheal intubation, resulting in a greater hypertensive response to intubation [26, 28] . Fiberoptic intubation can be performed either orally or nasally, and is less invasive than direct laryngoscopic intubation; however, this method also results in hemodynamic changes.
Several methods for reducing cardiovascular changes during endotracheal intubation have been studied.
Stoelting [8] stated that laryngotracheal lidocaine administration immediately prior to tracheal intubation reduced changes in blood pressure and led to spontaneous recovery of MBP and HR. Siedlecki [9] reported that blockade of beta adrenergic receptors reduced the intensity of cardiovascular disturbances. Alpha-2 agonists such as clonidine and dexmedetomidine are used to reduce stimulation of the sympathetic nervous system and hemodynamic changes during anesthetic induction [11] [12] [13] [14] [15] .
Opioids have also been used to prevent these changes [10] .
One such opioid is remifentanil; it effectively reduces hemodynamic changes during endotracheal intubation [16, [29] [30] [31] . This short-acting opioid has a rapid onset and a blood-brain equilibrium half-time of 1 to 2 minutes [17] .
It has a short context-sensitive half-time of 3 minutes, regardless of infusion time and does not accumulate, even in patients with hepatic or renal failure [16, 17] . For these reasons, remifentanil is an optimal choice during the In this study, we administered remifentanil after initiating an infusion of propofol at 4 μg/mL. Many studies have reported the concentration of propofol required to produce appropriate unconsciousness during intravenous anesthesia; the propofol Ce required for loss of consciousness in 90% of patients is 4 μg/mL [32, 33] .
Vuyk et al. [33] reported the EC 50 and EC 95 of propofol (to induce unconsciousness in 50% and 95% of patients, respectively) as 3.4 μg/mL and 4.34 μg/mL, respectively.
Another study reported that the Ce of propofol required to maintain the BIS at 41.1 ± 2.5 was 3.5 μg/mL [34] . or more patients in sequential trials. Therefore, while the sample size in this study was sufficient for the up-anddown method, the CIs for the EC50 and EC95 were unrealistically wide. We calculated the EC 50 and EC 95 using two statistical methods: a nonparametric turning point estimator and a parametric probit estimator. In the turning point estimator, the midpoint concentrations of crossovers were averaged. This method is commonly used in anesthesia up-and-down method studies [36] . The probit estimator method has been censured for some biases in its accuracy. This method has been adapted to the non-independence of up-and-down data; however, tolerance distribution symmetry is necessary [37] . For this reason, researchers should consider the use of an isotonic regression estimator with CI derived from boot strapping.
This is a well-described variant of restricted least squares regression that constrains the point estimates as either monotonic increasing or monotonic decreasing [38] . This statistical method may be constant over a range of doses. Another consideration in this study is the degree of cardiovascular changes in patients after infusion of propofol and remifentanil. Substantial changes in cardiovascular status may render it clinically difficult to administer propofol and remifentanil in combination, and may require the use of inotropic agents such as ephedrine. In our study, reductions in HR and MBP after administration of propofol and remifentanil were not clinically meaningful and did not require the administration of inotropic agents.
In conclusion, we found that the EC 50 of remifentanil needed to minimize hemodynamic responses to fiberoptic nasotracheal intubation, calculated by the Dixon up-anddown method, is 3.11 ± 0.38 ng/mL, with a propofol Ce of 4 μg/mL. In a probit analysis, the EC50 was 3.43 ng/mL (95% CI, 2.90-4.06 ng/mL) and the EC 95 was 4.52 ng/mL (95% CI, 3.96-9.03 ng/mL). The patients in this study maintained cardiovascular stability during fiberoptic nasotracheal intubation by remifentanil infusion.
